

APPENDIX 4. (Continued).

Quality Assessment		Summary of Findings										
No. of Patients		Effect										
No. of Studies	Design	Limitations	Inconsistency	Quality	Indirectness	Imprecision	Other Considerations	Extensively Hydrolyzed Milk Formula	Soy Formula	Relative (95% CI)	Absolute Severe symptoms of CMA (severe laryngeal edema, severe asthma, anaphylaxis) (follow-up 12 and 24 months)	Importance
0	-	-	-	-	-	-	-	-	-	-	-	Important Mild laryngeal edema or mild asthma (follow-up 12 months)
1	Randomized trials	No serious limitations ^{†*}	No serious inconsistency	No serious indirectness	Serious ^{***}	None	67/30	1/30	Rate ratio 66.7 (9.2 to 482.8)	-	⊕⊕⊕0 Moderate	Important Mild asthma (children with history of asthma) (follow-up 6 months)
1	Randomized trials	No serious limitations	No serious inconsistency	No serious indirectness	Serious ^{††}	None	198/13	28/7	Rate ratio 3.8 (2.9 to 216.3)	-	⊕⊕⊕0 Moderate	Important
2	Randomized trials	No serious limitations*	No serious inconsistency	No serious indirectness	Serious ^{**}	None	52/43	1/37	Rate ratio 16.9 (4.5 to 63.3)	-	⊕⊕⊕0 Moderate	Important Abdominal pain or vomiting (follow-up 6 and 12 months)
2	Randomized trials	No serious limitations*	No serious inconsistency	No serious indirectness	Serious ^{††}	None	537/43	17/37	Rate ratio 25.8 (5.9 to 113.6)	-	⊕⊕⊕0 Moderate	Important Rhinitis and/or conjunctivitis (follow-up 12 months)

APPENDIX 4. (Continued).

Quality Assessment		Summary of Findings											
No. of Studies	Design	Limitations	Inconsistency	Quality	Indirectness	Imprecision	Other Considerations	Extensively Hydrolyzed Milk Formula	Soy Formula	Rate ratio	Relative (95% CI)	Absolute Severe symptoms of CMA (severe laryngeal edema, severe asthma, anaphylaxis) (follow-up 12 and 24 months)	Importance
1	Randomized trials	Serious ⁴¹	No. serious inconsistency	No. serious indirectness	Serious ^{††}	None	31/30	2/30	2.7 (1.3 to 4.2)	---	---	⊕⊕00 Low	Important Lip/mouth pruritus and/or perioral urticaria (follow-up 6 and 12 months) Important
2	Randomized trials	No serious limitations [*]	Serious ^{§§}	No serious indirectness	Serious ^{††}	None	1369/43	110/37	Not pooled ⁴¹	Not pooled	---	⊕⊕00 Low	Important Lip/mouth pruritus and/or perioral urticaria (follow-up 6 and 12 months) Important

*One of the studies was not blinded. There is some uncertainty to what extent this might have influenced the results, especially reporting of adverse effects. However, we did not downgrade for risk of bias because we already downgraded the quality of evidence for imprecision and likelihood of publication bias.
[†]There is some uncertainty if the single challenge with milk reflects long term tolerance.
^{††}There were only 17 events and the confidence interval was very wide.
[‡]Only 2 small studies showing very large effect on beneficial outcomes and very little information about adverse effects.
[§]Very small baseline risk.
^{§§}There were only 22 events and the confidence interval was very wide.
^{†††}Only one study reported exacerbations of eczema. No study reported any other measure of the severity of eczema.
^{††††}Only 2 events, results do not exclude an appreciable benefit or appreciable harm.
^{†††††}40 events among 79 patients.
^{††††††}Study was not blinded. There is some uncertainty to what extent this might have influenced the results, especially reporting of adverse effects.
^{†††††††}Only 60 patients.
^{††††††††}No explanation was provided
^{†††††††††}Only 20 patients.
^{††††††††††}Only 80 patients.
^{§§§§}In one unblinded study that used whole milk local reactions were 83 times more frequent (95% CI: 37.2–185.6) in immunotherapy group compared to control group. In the other, blinded study that used preparation of dry nonfat powdered milk the rate of local reactions in children given immunotherapy was 4.5 times higher (95% CI: 3.35–5.19).

平成 22 年度厚生労働科学研究費補助金
免疫アレルギー疾患等予防・治療研究事業

「アレルギー疾患の全国全年齢有症率および
治療ガイドライン普及効果等疫学調査に基づく発症要因・
医療体制評価に関する研究」研究報告書

発行 平成 23 年 3 月 31 日
発行者 東京都立小児総合医療センター アレルギー科
赤澤 晃
〒183-8561 東京都府中市武蔵台 2-8-29

